Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eisai Co. Ltd (ESAIY)

Eisai Co. Ltd (ESAIY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.8700 +3.30%
on 11/07/24
9.1500 -11.15%
on 10/15/24
-0.9900 (-10.86%)
since 10/11/24
3-Month
7.8700 +3.30%
on 11/07/24
10.7500 -24.37%
on 08/22/24
-1.2400 (-13.23%)
since 08/12/24
52-Week
7.8700 +3.30%
on 11/07/24
13.5699 -40.09%
on 12/12/23
-4.7700 (-36.98%)
since 11/10/23

Most Recent Stories

More News
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi

Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout.

ESAIY : 8.1300 (-0.61%)
BIIB : 168.28 (-2.18%)
LLY : 818.86 (-1.63%)
XLV : 147.22 (-1.39%)
ESALY : 61.5100 (-2.11%)

Key Turning Points

3rd Resistance Point 8.2633
2nd Resistance Point 8.2167
1st Resistance Point 8.1733
Last Price 8.1300
1st Support Level 8.0833
2nd Support Level 8.0367
3rd Support Level 7.9933

See More

52-Week High 13.5699
Fibonacci 61.8% 11.3925
Fibonacci 50% 10.7199
Fibonacci 38.2% 10.0474
Last Price 8.1300
52-Week Low 7.8700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar